KC-2554

293T-cyno-CLDN18.2 Cell Line

×
24292
Home » 293T-cyno-CLDN18.2 Cell Line

Background of 293T-cyno-CLDN18.2 Cell Line

CLDN18 encodes claudin 18 and is also known as SFTA5. Claudins are integral membrane proteins and components of tight junction strands. Tight junction strands serve as a physical barrier to prevent solutes and water from passing freely through the paracellular space between epithelial or endothelial cell sheets, and also play critical roles in maintaining cell polarity and signal transductions. This gene is upregulated in patients with ulcerative colitis and highly overexpressed in infiltrating ductal adenocarcinomas. PKC/MAPK/AP-1 (protein kinase C/mitogen-activated protein kinase/activator protein-1) dependent pathway regulates the expression of this gene in gastric cells. Alternatively spliced transcript variants encoding different isoforms have been identified.

Specifications

Catalog NumberKC-2554
Cell Line Name293T-cyno-CLDN18.2 Cell Line
NCBI/UniProt Accession NumberNM_001002026
Host Cell Line293T
Description293T-cyno-CLDN18.2 is a stable engineered cell line expressing cyno CLDN18.2
QuantityOne vial of frozen cells (≥2×10⁶ cells/vial)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% DMEM+20% FBS+10% DMSO
Propagation MediumDMEM+10%FBS+1μg/mL Puromycin
Selection MarkerPuromycin
MorphologyEpithelial
SubcultureSplit at a ratio of 1:4–1:6 every 2–3 days
Incubation37 °C with 5% CO₂
StorageLiquid nitrogen immediately upon receiving
Doubling TimeEstimated 19–36 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

293T-cyno-CLDN18.2 cell line was generated using a lentiviral vector expressing the cyno CLDN18.2 sequence.

Characterization

Figure 1: Characterization of cyno-CLDN18.2 overexpression in the 293T-cyno-CLDN18.2 stable clone using FACS.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO₂ incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4–1:6 every 2–3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the pellet in chilled freezing medium, ensuring a minimum cell density of 3×10⁶ cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

  1. Lee H, Ha SY, Kim S et al. Deep learning prediction of MSI/dMMR, EBV, HER2, PD-L1, and CLDN18.2 status directly from hematoxylin and eosin-stained slides in gastric and gastroesophageal junction adenocarcinoma: a systematic review. Frontiers in oncology. 2026;16:1953562. PMID: 42857070. doi: 10.3389/fonc.2026.1953562.
  2. Katoh M, Katoh M CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapy. Frontiers in molecular medicine. 2026;6:1927389. PMID: 42857022. doi: 10.3389/fmmed.2026.1927389.
  3. Yuan Y, Yan H, Wu Q Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials. Investigational new drugs. 2026 Oct 8;:. PMID: 42848149. doi: 10.1007/s10637-026-01635-x.

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.